Smooth muscle cells (SMCs) are the main cell type in intimal thickenings and some stages of human atherosclerosis. Like monocyte-derived macrophages, SMCs accumulate excess lipids and contribute to the total intimal foam cell population. In contrast, apolipoprotein (Apo)E-deficient and LDL receptor-deficient mice develop atherosclerotic lesions that are macrophage-as opposed to SMC-rich. The lesser contribution of SMCs to lesion development in these mouse models has distracted attention away from the importance of SMC cholesterol homeostasis in the artery wall. Intimal SMCs accumulate excess amounts of cholesteryl esters when compared with medial layer SMCs, possibly explained by reduced ATP-binding cassette transporter A1 expression and ApoA-I binding to intimal-type SMCs. The aim of this review is to compare the relative contribution of monocyte-derived macrophages and SMCs to human vs. mouse atherosclerosis, and describe what is known about lipid uptake and removal mechanisms contributing to arterial macrophage and SMC foam cell formation. An increased understanding of the contribution of these cell types to lesion development will help to delineate their relative importance in atherogenesis and as potential therapeutic targets.
Introduction
In the current model of atherosclerosis initiation, 1 apolipoprotein B-containing lipoproteins diffusing from plasma into the subendothelial space are retained and undergo aggregation and oxidative modifications. Injury to the vascular endothelium by multiple mechanisms including the presence of these retained lipoproteins leads to infiltration and retention of monocytes and lymphocytes in the subendothelial space. Subsequently, monocytes differentiate into macrophages, accumulate lipids from these retained lipoproteins, and turn into foam cells. While this is occurring, smooth muscle cells (SMCs) migrate into and proliferate in the intima. Like macrophages, SMCs have also been shown to take up lipids and transform into foam cells, contributing to lesion development and progression. 2 -4 SMCs and SMC foam cells, however, are not as evident in mouse models of atherosclerosis as they are in human lesions. 5 This has led, we propose, to an underemphasis of SMCs as a repository of excess lipids in the plaque. Unlike mouse models, which have a very thin and SMC-poor intima prior to and in early stages of atherosclerosis, 5 SMCs are a major component of the intima in human atherosclerosisprone arteries even before they show any evidence of atherosclerosis. 6, 7 Extracellular lipid deposition in the intima has been observed in early stages of atherosclerosis in both human and mouse models. 8 -10 While in humans, this lipid deposition occurs in an SMC-and extracellular matrix-rich area, in mouse models, lipids appear to deposit in a narrow subendothelial space with very few SMC and extracellular matrix (ECM). 5 SMCs in developing lesions in humans, therefore, are in close and constant contact with lipids accumulated in the intima prior to their engulfment by SMCs and macrophages in the intima.
In both macrophages and SMCs, several processes including lipoprotein uptake, cholesteryl ester (CE) hydrolysis, intracellular cholesterol transport and esterification, activation of cholesterol efflux-related genes by oxysterols, and efflux of cholesterol from cells are key factors in cellular cholesterol homeostasis. The balance between accumulation of cholesterol from atherogenic lipoproteins and the removal of this cholesterol by apolipoprotein (Apo)A-I and HDL particles from the cells are key factors predicting the presence of foam cells in lesions. In this regard, scavenger receptors and ATP-binding cassette (ABC) transporters play important roles in foam cell formation as they regulate the influx and efflux of lipids, respectively. The focus of this review is to compare the contribution of monocytederived macrophages and SMCs to the total foam cell population in human and mouse models of atherosclerosis, and what is currently known about cholesterol homeostatic pathways that lead to foam cell formation in macrophages and SMCs. 26 Investigating the role of DCs in human atherosclerosis is more complicated. The presence of DC foam cells has been reported using electron microscopy of human thoracic artery lesions. 27 DCs, however, display a remarkable heterogeneity in human atherosclerotic lesions, and there is so far no universal marker to identify DCs from other cell types or between subtypes of DCs in the artery wall. 28, 29 The contribution of DCs to the total foam cell population in human atherosclerotic lesions requires further investigation. The contribution of monocyte-derived macrophages, SMCs, and DCs to the total lesion foam cell population in human atherosclerosis has not been elucidated. CD68, which has been used extensively to characterize macrophages in atherosclerotic lesions, 30 41 and glycolaldehyde (an advanced glycation end product)-modified LDL. 42 Aggregated LDL, another lipoprotein ligand involved in foam cell formation, has been reported to be taken up by LDLr-mediated phagocytosis 37 and receptor-independent pathways, 43 but not via scavenger receptors. 44, 45 Another likely pathway in lipoprotein uptake and foam cell formation is the very LDL (VLDL) receptor, which mediates the uptake of VLDL and intermediate-density lipoprotein to induce foam cell formation in both macrophages 46 and SMCs. 18, 47 Expression of the VLDL receptor has been reported in both human macrophages and SMCs. 48 This receptor likely has an important role in foam cell development under conditions of increased plasma triglyceride-rich lipoproteins, as occur post-prandially, in type 2 diabetes, and in individuals with remnant removal disease. 49 Receptor-independent mechanisms including macro-and micropinocytosis of extracellular fluid have also been shown to be involved in uptake of native LDL by macrophages and to induce foam cell formation. 44, 50, 51 These mechanisms of cholesterol uptake by macrophages have also been found to contribute to plaque macrophage foam cell formation in ApoE-deficient mice. 52 The role of fluid-phase pinocytosis mechanisms in cholesterol uptake by SMCs has not yet been explored. Lipid loading of macrophages and SMCs leads to alterations in gene expression and function. Macrophage foam cells show both an increase and a decrease in expression of pro-inflammatory genes. 53 Lipid loading of SMCs is associated with expression of pro-inflammatory cytokines. 54, 55 Fisher's group has demonstrated that mouse SMCs, in addition to expressing macrophage markers, acquire phagocytic properties after cholesterol loading. 3 Lipid loading has also been shown to impair collagen and fibronectin assembly in SMCs, 18 which may lead to vulnerable atherosclerotic plaques. Expression of matrix metalloproteinases in atherosclerotic lesions also contributes to plaque instability. 56 Both macrophage and SMC foam cells express matrix metalloproteinases in atherosclerotic plaques. 57 oxLDL can induce apoptosis in macrophages 58 and SMCs. 59 Moreover, accumulation of free cholesterol (FC) in foam cells, as seen in advanced atherosclerotic lesions, is highly toxic and leads to cell death in macrophages 60 but not in SMCs. 61 Statins have been shown to inhibit the secretion and activity of metalloproteinases in vascular SMCs and macrophage foam cells, 62 reduce the size of lipid-rich necrotic core and local plaque inflammation, and lead to an overall improvement in plaque stability. 56 It is expected that these effects of statins in vivo would be similar in intimal smooth muscle foam cells and monocyte-derived macrophage foam cells.
Lipid uptake and scavenger receptors
Expression of scavenger receptors has been documented in both macrophages and SMCs in human and mouse atherosclerotic lesions ( Figure 1) . 63 -66 Each scavenger receptor has a broad specificity, but there is also a preference for certain ligands. Even though a reduction in atherosclerotic lesion size in specific scavenger receptor knockout animals has been observed, 67, 68 the presence of foam cells in the remaining lesions indicates a high degree of redundancy of activity by the various scavenger receptors mediating foam cell formation.
Scavenger receptor expression by macrophages
Macrophages express a variety of scavenger receptors including scavenger receptor class A (SR-A) types I and II, CD36, 69 LOX-1, 70 CD68, 71 and scavenger receptor class B type I (SR-BI). 72, 73 Using SR-A and CD36 double knockout mice, Kunjathoor et al. 74 found that SR-A and CD36 are the principal receptors mediating uptake of modified lipoproteins by macrophages in vitro. However, silencing either SR-A or CD36 has resulted in both reduction 67, 75 or enhancement 45 of atherosclerotic lesion formation in ApoE-and LDLr-deficient mice. Manning-Tobin et al.
found that knocking out both SR-A and CD36 in ApoE-deficient mice resulted in no decrease in atherosclerotic lesion area or in vivo foam cell formation when compared with ApoE-deficient mice expressing these receptors. However, they found that loss of SR-A and CD36 prevented the progression of atherosclerosis to advanced complex lesions. 76 The role of CD68 as a scavenger receptor for oxLDL is controversial. 77, 78 Recently, Song et al. 17 showed that macrophages from CD68-deficient mice have no defect in oxLDL uptake compared with macrophages from wild-type mice. SR-BI is expressed in macrophages both in culture and human atherosclerotic lesions. 72, 73 Whether SR-BI mediates net uptake of lipids by macrophages, however, is uncertain. found that oleic acid induces smooth muscle foam cell formation through a CD36-dependent pathway in ApoE-deficient mice. SMC of human atherosclerotic lesions has been shown to express SR-BI. 73 Yeh et al. 83 found expression of SR-BI in rat SMCs both in vitro and in vivo. However, in another report, no detectable levels of SR-BI were found in cultured human and rat SMC lines. 84 The role of SR-BI in net lipid uptake by SMCs has also not yet been determined.
Lipid uptake by medial-vs. intimal-type SMCs
The tendency of SMCs to accumulate CE appears to be variable among different SMC phenotypes. The main subtype of SMCs in the intimal layer has an epithelioid or cuboidal morphology, is less differentiated, synthesizes larger amounts of ECM, expresses lesser amounts of SM a-actin and myosin heavy chain, and can accumulate more CEs 4,16,85 than medial layer SMCs, which have a predominantly spindle morphology and contractile phenotype. 86 Li et al. 87 found that expression of scavenger receptors is higher in intimal compared with adjacent medial SMC in rabbit atherosclerotic lesions. Cytokines such as tumour necrosis factor-a (TNF-a), interferon-g (IFN-g), 87 plateletderived growth factor-BB, and transforming growth factor-b 1 , 88 which can stimulate phenotypic modulation of SMCs, have also been shown to increase expression and activity of scavenger receptors in SMCs.
Cholesterol esterification and hydrolysis of CEs
Lipoprotein-derived CEs are first digested in late endosomes/lysosomes by lysosomal acid lipase. 89 Lysosomally derived FC then traffics within the cell, including to the endoplasmic reticulum (ER) where it has multiple regulatory effects. Excess FC is converted to CE by the enzyme acyl-coenzyme A (CoA):cholesterol acyltransferase (ACAT). This CE is then hydrolyzed back to FC by CE hydrolases, making this cholesterol available for efflux. In both macrophages 90 and SMCs 91 alterations of intracellular cholesterol trafficking and the esterification cycle have been shown to affect intracellular CE accumulation.
Acyl-CoA:cholesterol acyltransferase
ACAT has two isoforms, ACAT-1 and ACAT-2. ACAT-1 has a ubiquitous expression in many tissues but ACAT-2 is only expressed in intestinal enterocytes, hepatocytes, and macrophages. 92, 93 Expression of ACAT-1 and -2 significantly increases after differentiation of monocytes to macrophages. 93, 94 Moreover, different mediators including IFN-g, 95 urotensin II, 96 and TNF-a 97 up-regulate the expression of ACAT-1 in macrophages. Unlike macrophages, regulation of expression and activity of ACAT in SMCs has received little attention. Rong et al. 61 found an increase in ACAT-1 activity after cholesterol loading in both rat and human aortic SMCs. ACAT-2 was not found to be expressed by arterial SMCs. 93 
CE hydrolases
Several neutral hydrolases have been identified to mediate CE hydrolysis in the cytoplasm. 98 Recently, a role for lysosomal acid lipase in CE hydrolysis in macrophages has also been identified. 99 The extent of contribution of cytoplasmic (neutral) CE hydrolase and lysosomal acid lipase in total CE hydrolytic activity and cholesterol efflux in macrophage and SMCs has not yet been revealed.
Cholesterol removal pathways
The other critical determinant of cholesterol homeostasis in foam cells is the removal of excess cell cholesterol, the first step in reverse transport of cholesterol back to the liver for excretion from the body (Figure 1) . Cholesterol removal from cells is mediated by ABC transporters and possibly SR-BI, processes that may be different between macrophages and SMCs. Another mechanism of cholesterol removal from cells, passive diffusion, 100 is not expected to be different between these cell types and is not discussed further here.
ABC transporters
Four members of the membrane transporter ABC superfamily control the delivery and disposal of cholesterol. ABCG5 and ABCG8 inhibit intestinal absorption of dietary sterols and promote hepatobiliary secretion of sterols, while ABCA1 and ABCG1 enhance cholesterol removal from cells and have important roles in the reverse cholesterol transport pathway. 101 
ABC transporter A1
ABC transporter A1 (ABCA1)-mediated efflux of cholesterol and phospholipids to apolipoprotein A1 (ApoA-I) and other HDL apolipoproteins to form nascent HDL is considered the rate-limiting step in the reverse cholesterol transport pathway. 102, 103 Increased cell cholesterol levels lead to increased formation of oxysterols, which up-regulate ABCA1 expression by binding to the nuclear receptor liver X receptor (LXR) (Figure 1) . 104, 105 LXR and its obligate heterodimer partner retinoid X receptor, activated by retinoic acid, bind to response elements within the ABCA1 gene promoter to activate ABCA1 transcription. 105, 106 In this regard, the rate of flux of cholesterol out of late endosomes/lysosomes and the consequent oxysterol formation is a key regulator of ABCA1 expression and activity. 107 -109 Increased ABCA1 expression thereby serves to mobilize excess cholesterol from cholesterol-overloaded cells and, in the process, generate new HDL particles. This process of lipidation of HDL apolipoproteins by ABCA1 in order to make nascent HDL particles and remove cholesterol from cells has been documented in macrophages 110, 111 and SMCs.
84,112
ABCA1 regulation and activity in macrophages
Regulation of ABCA1 and its role in cholesterol removal from macrophages has been the focus of many studies. 27-hydroxycholesterol, the product of sterol-27-hydroxylase-also known as CYP27A1, is the oxysterol with LXR-activating activity in highest abundance 113, 114 and, therefore, the likely key regulator of LXR activity, in the artery wall. Recent studies have shown that overexpression of CYP27A1 in mouse macrophages increases ABCA1 expression and cholesterol efflux to ApoA-I. 115, 116 In this respect, Taylor et al. 117 have shown that enhancement of cholesterol delivery to mitochondrial sterol 27-hydroxylase (Cyp27) by steroidogenic acute regulatory protein (StARD1) leads to an increase in ABCA1 expression and cholesterol efflux in murine macrophages.
In addition to transcriptional regulation of ABCA1 by LXR, regulation of ABCA1 protein stability and degradation also plays an important role in modulation of ABCA1 expression and activity. Bowden et al. found that oxysterol-binding protein can negatively regulate ABCA1 expression and cholesterol efflux in macrophages by decreasing protein stability. 118 Binding of ApoA-I to ABCA1 has been shown to prevent ABCA1 degradation after internalization and enhance recycling of ABCA1 to the surface. 119 Moreover, calpain-mediated degradation as a result of phosphorylation of a proline, glutamic acid, serine, and threonine (PEST) sequence of ABCA1 can be inhibited by ApoA-I. 120, 121 Iwamoto et al. 122 found that calmodulin binds ABCA1 and prevents its degradation. GTPase Rab8 has been shown to increase the amount of ABCA1 protein and regulate ABCA1 trafficking to the plasma membrane in primary human macrophages. 123 
ABCA1 regulation and activity in SMCs
Unlike macrophages, regulation of ABCA1 in SMCs has received little attention. We found differential expression of ABCA1 between medial and intimal SMCs both in vivo and in vitro. 4 Our data showed low basal and cholesterol-stimulated levels of ABCA1 mRNA and protein in cultured intima-like SMCs when compared with medialtype SMCs, and low ABCA1 protein levels in human coronary artery intimal SMCs compared with medial SMCs. 4 Similar low levels of ABCA1 expression were seen in cultured human and Sprague-Dawley rat intimal-type SMCs when compared with their medial-type counterparts. We were able to induce the expression of ABCA1 in epithelioid SMCs using exogenous LXR agonists. 4 This suggests that intimal SMCs have a defect in generating the oxysterols necessary to activate LXR and up-regulate ABCA1 expression, currently under investigation in our laboratory.
ApoA-I binding in macrophages and SMCs
A direct binding interaction between ApoA-I and ABCA1 and/or a cellular association of ApoA-I with lipid domains formed by ABCA1 are necessary for ApoA-I-mediated cholesterol removal from cells. 124, 125 The ability of ApoA-I to be cross-linked to ABCA1 has been documented in different cell types including macrophages. 126, 127 This surface binding of ApoA-I has been shown to be correlated with the level of expression of functional ABCA1 in macrophages. 128 Previous reports using SMCs derived from the aortas of several animal species 129 -131 had indicated that aortic SMCs are resistant to HDL-and free ApoA-I-mediated cellular lipid efflux. We compared two human aortic SMC lines with two rat aortic SMC lines and found that human ApoA-I binds with high affinity and efficiently mediates both cholesterol and phospholipid efflux from human but not rat aortic SMCs. This difference was not explained by species differences in ApoA-I or different levels of SR-BI expression between human and rat SMCs lines. 84 We found much higher levels of ApoA-I binding and cross-linking to ABCA1 by cultured medial-than by intimal-type SMCs in both non-cholesterol-loaded and cholesterol-loaded conditions. 4 Overexpression of ABCA1 in intimal-type SMCs failed to improve ApoA-I binding and lipid efflux from these cells. 4 These data suggest that different phenotypes of SMCs may exhibit a differential ability to bind as well as release lipids to ApoA-I.
ABC transporter G1
ABCG1 is an ABC half-transporter that actively transports sterols, including FC to preformed HDL. Like ABCA1, expression of ABCG1 is highly regulated by the nuclear receptor LXR. 4 suggests that ABCG1 regulation would also be impaired in these cells; however, this remains to be investigated.
Scavenger receptor BI
In addition to being a cell surface receptor that mediates lipid uptake from lipoproteins, SR-BI also facilitates a gradient-dependent efflux of FC from cells to HDL. 142, 143 The overall role of SR-BI in macrophage cholesterol efflux, however, is not yet clear. Some studies have found a significant role for SR-BI, 144 while others have failed to show any significant SR-BI-dependent cholesterol efflux from macrophages. 145, 146 Transplantation of SR-BI-deficient bone marrow-derived cells into LDLr-and ApoE-deficient mice indicates an atheroprotective effect of SR-BI in macrophages; however, it is not clear that this protection is related to cholesterol efflux. 145, 147 A recent study by Ji et al.
148
found that SR-BI stimulates cellular cholesterol efflux from macrophages; however, this did not result in any detectable reduction in cellular cholesterol mass. Whether SR-BI plays any significant role in cholesterol efflux from intimal or medial SMCs remains to be explored.
Conclusions and future directions
The relative contribution of SMCs and macrophages to the development of atherosclerosis, especially at early stages, is different between humans and mouse models. A fundamental question remaining to be answered regarding cholesterol homeostasis in the human atherosclerotic plaque is the relative contribution of monocyte-derived macrophages, SMCs, and DCs to total lesion foam cell formation. Lack of specific markers for human monocyte-derived macrophages, SMCs, and DCs makes identification of these cells in human atherosclerotic lesions by means of immunohistochemistry challenging. This suggests that in order to characterize the origin of different cell types in atherosclerotic lesions, it is crucial to use lineage-specific markers. Such a marker has been identified within the promoter region of SMC genes including SM a-actin and SM myosin heavy chain (SM-MHC), 149, 150 and can potentially be used as a marker of SMC lineage identity. Further studies are needed to determine and focus attention on the major cell types accumulating excess cholesterol in the human artery wall. The findings that ABCA1 expression is low in cultured intimal-type and human atherosclerotic lesion SMCs and that ApoA-I binding is also impaired in cultured intimal SMCs may represent major defining differences between SMCs and monocyte-derived macrophages in lesion foam cell development.
